Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 35, Issue 5, Pages 1008-1018Publisher
SPRINGER
DOI: 10.1007/s00259-007-0658-0
Keywords
breast cancer; molecular imaging; HER2; PET; F-18
Funding
- Intramural NIH HHS [Z01 BC010727-02, Z01 BC010727-01] Funding Source: Medline
- NCI NIH HHS [N01CO12400, N01-CO-12400, N01-CO-12401, N02CO12401] Funding Source: Medline
Ask authors/readers for more resources
Purpose The expression of human epidermal growth factor receptor-2 (HER2) receptors in cancers is correlated with a poor prognosis. If assessed in vivo, it could be used for selection of appropriate therapy for individual patients and for monitoring of the tumor response to targeted therapies. We have radiolabeled a HER2-binding Affibody molecule with fluorine-18 for in vivo monitoring of the HER2 expression by positron emission tomography (PET). Materials and methhods The HER2-binding Z(HER2:342)-Cys Affibody molecule was conjugated with N-2-(4-[F-18]fluorobenzamido)ethylmaleimide ([F-18]FBEM). The in vitro binding of the resulting radioconjugate was characterized by receptor saturation and competition assays. For in vivo studies, the radioconjugate was injected into the tail vein of mice bearing subcutaneous HER2-positive or HER2-negative tumors. Some of the mice were pre-treated with non-labeled Z(HER2:342)-Cys. The animals were sacrificed at different times post-injection, and the radioactivity in selected tissues was measured. PET images were obtained using an animal PET scanner. Results In vitro experiments indicated specific, high-affinity binding to HER2. PET imaging revealed a high accumulation of the radioactivity in the tumor as early as 20 min after injection, with a plateau being reached after 60 min. These results were confirmed by biodistribution studies demonstrating that, as early as 1 h post-injection, the tumor to blood concentration ratio was 7.5 and increased to 27 at 4 h. Pre-saturation of the receptors with unlabeled Z(HER2:342)-Cys lowered the accumulation of radioactivity in HER2-positive tumors to the levels observed in HER2-negative ones. Conclusion Our results suggest that the [F-18]FBEM-Z(HER2:342) radioconjugate can be used to assess HER2 expression in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available